RxDoctor Payments Data

Nicole Green

Family · Destrehan, LANPI 1104105352

Payments from drug & device makers

$3,400in general payments, 2019–2025

Across 193 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$483
  • AstraZeneca$206
  • Teva Pharmaceuticals USA, Inc.$185
  • Boehringer Ingelheim$172
  • Novo Nordisk$154
  • plus $887 from 16 others

What the payments were for

  • Food & beverage$3,400100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,400 in reported general payments places this provider in the 85th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide128$177,871
MounjaroTirzepatide119$153,087
LinzessLinaclotide49$67,456
JardianceEmpagliflozin35$48,858
TrulicityDulaglutide34$39,192
JanuviaSitagliptin Phosphate26$33,231
XareltoRivaroxaban16$24,627
RybelsusSemaglutide13$23,923
EliquisApixaban17$21,388
VraylarCariprazine Hcl15$20,611
FarxigaDapagliflozin Propanediol13$16,266
Breo ElliptaFluticasone/Vilanterol19$8,362
Albuterol Sulfate HfaAlbuterol Sulfate163$5,397
Lidocaine37$5,045
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm14$4,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$154$201,794141 claims
Lilly USA, LLCMounjaro, Trulicity$483$192,279153 claims
AbbVieLinzess, Vraylar$1,314$88,06664 claims
Boehringer IngelheimJardiance$172$48,85835 claims
MerckJanuvia$14$33,23126 claims
Johnson & JohnsonXarelto$72$24,62716 claims
PfizerEliquis$136$21,38817 claims
AstraZenecaFarxiga, Symbicort$206$19,40825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,610 family providers in Louisiana.

Other family in Destrehan

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →